What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 7.1% from 2023 to 2028.

What are the key drivers of the Crohn’s Disease Therapeutics market?

Increasing prevalence and rising awareness are key drivers of the market.

What are the major challenges faced by the Crohn’s Disease Therapeutics market?

High treatment costs and limited access to healthcare are major challenges.

Which regions are leading the Crohn’s Disease Therapeutics market?

North America and Europe are leading the market due to high awareness.

Who are the top companies in the Crohn’s Disease Therapeutics market?

Top companies include Johnson & Johnson and AbbVie due to their strong product portfolios.

What are the future opportunities in the Crohn’s Disease Therapeutics market?

Emerging markets and innovative therapies offer future opportunities for growth.

How is technology impacting the Crohn’s Disease Therapeutics market?

Advances in biotechnology are driving innovation in the market.

What is the current regulatory landscape for the Crohn’s Disease Therapeutics market?

The regulatory landscape is complex with stringent approval processes.

What is the future outlook for the Crohn’s Disease Therapeutics market?

The future outlook is positive with increasing demand for effective treatments.

Crohn’s Disease Therapeutics Market Comprehensive Report: 200+ Pages | 2026–2034

Crohn’s Disease Therapeutics by Application (Hospitals, Ambulatory Surgical Centers), by Types (Non-Surgical, Surgical), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $13.7 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $13.7 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Crohn’s Disease Therapeutics Market Overview

The Crohn’s Disease Therapeutics market refers to the industry focused on developing and marketing treatments for Crohn’s disease, a type of inflammatory bowel disease. As the Crohn’s Disease Therapeutics market size is expected to grow significantly, driven by an increasing prevalence of the disease and the need for effective treatments, understanding the growth outlook, market forecast, and industry expansion is crucial for stakeholders. The scope of this market encompasses various therapeutic approaches, including biologics, small molecules, and biosimilars, aimed at managing symptoms, inducing remission, and improving the quality of life for patients. The current Crohn’s Disease Therapeutics market size is approximately $12.4 billion, with a projected growth forecast indicating a compound annual growth rate (CAGR) of around 7.5% from 2026 to 2033, driven by macro drivers such as advancements in biotechnology and personalized medicine.

Loading chart…

Key forces shaping the Crohn’s Disease Therapeutics industry include technology shifts towards more targeted and personalized therapies, regulations supporting the development of biosimilars, and changes in consumer behavior demanding more effective and safer treatments. The largest region for Crohn’s Disease Therapeutics is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare spending and a growing awareness of inflammatory bowel diseases. Understanding these dynamics is essential for strategic planners, C-suite executives, and business development teams seeking to navigate the complexities of the Crohn’s Disease Therapeutics market and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	13.70 million
Revenue forecast in 2033	24.98 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson and Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; UCB India Private Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Crohn’s Disease Therapeutics market is poised for significant growth, driven by increasing prevalence of the disease and advancements in treatment options. The growth forecast for the market is promising, with the Crohn’s Disease Therapeutics market size expected to expand substantially over the forecast period.

Growth Drivers2 items

Rising demand for biologic therapies, such as tumor necrosis factor-alpha (TNF-alpha) inhibitors, is driving the growth of the Crohn’s Disease Therapeutics market. This is due to their high efficacy in treating moderate to severe cases of the disease.

Increasing investments in research and development activities, focused on developing novel and more effective treatments, are also contributing to the growth of the market.

Restraints2 items

High costs associated with the development and manufacturing of biologic therapies are limiting their adoption in certain regions, thereby restraining the growth of the Crohn’s Disease Therapeutics market.

Stringent regulatory requirements and the need for lengthy clinical trials are also hindering the growth of the market, making it challenging for new treatments to enter the market.

Opportunities2 items

The growing personalized medicine trend presents opportunities for the development of targeted therapies, which can provide more effective treatment options for patients with specific genetic profiles.

The increasing adoption of digital health technologies is also creating opportunities for the development of innovative treatment approaches, such as telemedicine and remote patient monitoring.

Challenges2 items

Managing the supply chain and ensuring the timely delivery of biologic therapies to patients is a significant challenge, due to the complex manufacturing and storage requirements of these products.

The Crohn’s Disease Therapeutics market is also facing challenges related to pricing and reimbursement, as the high costs of biologic therapies can limit patient access to these treatments.

Market Segmentation

Loading chart…

The Application segment of the Crohn’s Disease Therapeutics market refers to the various uses of therapeutics in treating Crohn’s disease. This segment contributes significantly to the overall Crohn’s Disease Therapeutics market size, as it encompasses a wide range of applications, including the treatment of moderate to severe Crohn’s disease, maintenance therapy, and treatment of fistulizing Crohn’s disease. Understanding the Crohn’s Disease Therapeutics segmentation is crucial in identifying the target audience and developing effective treatment strategies.

The Types segment of the Crohn’s Disease Therapeutics market is categorized into subtypes, including [object Object] and [object Object]. This segmentation is essential in understanding the different therapeutic approaches used to treat Crohn’s disease, such as biologics, immunomodulators, and aminosalicylates. Each subtype has its unique characteristics, advantages, and disadvantages, and contributes to the overall market size. Analyzing the market taxonomy of the Crohn’s Disease Therapeutics market is vital in identifying the most effective treatment options and understanding the competitive landscape.

Crohn’s Disease Therapeutics Segmentation Breakdown6 items

Application

Hospitals

Ambulatory Surgical Centers

Types

Non-Surgical

Surgical

Regional Insights

Loading chart…

The Crohn’s Disease Therapeutics market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of novel therapeutics, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. Europe is driven by robust policies, a strong ecosystem, and significant investments in research and development. Asia Pacific is fueled by growing adoption, increasing infrastructure development, and large demographics. Latin America and Middle East & Africa are driven by improving infrastructure, growing adoption, and increasing investments in healthcare.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by increasing demand for effective Crohn’s Disease Therapeutics. The region's large patient population, rising awareness, and growing healthcare expenditure will contribute to its rapid growth. As the Crohn’s Disease Therapeutics market continues to evolve, understanding regional dynamics will be crucial for stakeholders to capitalize on emerging opportunities.

Competitive Landscape

The Crohn’s Disease Therapeutics market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Crohn’s Disease Therapeutics competitive landscape is characterized by high competition, with companies focusing on differentiation through product portfolios and strategic partnerships. Global players dominate the market, but local companies are also gaining traction through regional expansion and localization strategies.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on strategic initiatives that drive growth and differentiation.

Johnson and Johnson Services Inc. focuses on innovation pipeline

Pfizer Inc. prioritizes regional expansion

Allergan emphasizes premium pricing

AbbVie Inc. invests in vertical integration

Takeda Pharmaceutical Company Limited targets local manufacturing

Celgene Corporation explores OEM tie-ups

Key Crohn’s Disease Therapeutics Companies12 items

Johnson and Johnson Services Inc.

Pfizer Inc.

Allergan

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Celgene Corporation

Perrigo Company PLC

Ferring B.V.

Salix Pharmaceuticals

Gilead Sciences Inc.

Genentech Inc.

UCB India Private Limited

Market Ecosystem

The Crohn’s Disease Therapeutics ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers and suppliers to downstream channels and end users. This ecosystem is characterized by the creation and capture of value through the development, manufacturing, and distribution of therapeutic products for Crohn’s disease. The value chain analysis of this ecosystem reveals the intricate relationships between various participants, influencing the overall efficiency and effectiveness of the market.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce therapeutic products

Technology providers — develop innovative treatment technologies

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer patient support services

End users / buyers — receive therapeutic treatments

Regulators/standards bodies — establish treatment guidelines and approvals

The flow of value within the Crohn’s Disease Therapeutics ecosystem is influenced by various control points, including regulatory bodies and reimbursement authorities. Dependency risks, such as input constraints and standards compliance, can impact the efficiency of the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the relationships between ecosystem participants. The ecosystem's structure and dynamics may also differ by region, due to variations in healthcare systems, patient needs, and regulatory frameworks.

Recent Industry Insights

The Crohn’s Disease Therapeutics industry trends have witnessed significant developments over the last 12-18 months, shaping the future of the market. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have focused on developing innovative treatments and improving patient outcomes. Notable mergers and acquisitions have also taken place, with companies seeking to expand their product portfolios and strengthen their positions in the market.

Furthermore, several product and technology launches have been announced, offering new treatment options for patients with Crohn’s disease. Regulatory changes, including updated guidelines and approvals, have also impacted the industry. Additionally, there has been a shift in consumer trends, with growing demand for personalized and targeted therapies. Funding rounds and expansions have supported the development of new treatments, driving growth in the Crohn’s Disease Therapeutics market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Crohn's Disease Therapeutics market outlook. The market attractiveness is moderate, driven by increasing prevalence and a growing need for effective treatments. Competitive intensity is high, with several key players investing heavily in research and development. The long-term outlook is promising, with a focus on innovative therapies and personalized medicine.

The innovation landscape is evolving, with a shift towards biologics and gene therapies. Demand-supply balance is a concern, with a shortage of effective treatments for severe cases. Key risk factors include regulatory challenges, patent expirations, and reimbursement issues. Overall, the Crohn's Disease Therapeutics market is expected to experience steady growth, driven by advances in medical technology and an increasing focus on patient-centric care.

11 items

1. Executive Summary

2. Crohn’s Disease Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Crohn’s Disease Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.2. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Non-Surgical

6.2.2. Surgical

6.3. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Crohn’s Disease Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Crohn’s Disease Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Crohn’s Disease Therapeutics Market Competition by Key Manufacturers

8.1. Global Crohn’s Disease Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Crohn’s Disease Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson and Johnson Services Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Allergan

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AbbVie Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Takeda Pharmaceutical Company Limited

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Celgene Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Perrigo Company PLC

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ferring B.V.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Salix Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Gilead Sciences Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Genentech Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. UCB India Private Limited

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Crohn’s Disease Therapeutics Market

Figure 4: Global Crohn’s Disease Therapeutics Market: Drivers

Figure 5: Global Crohn’s Disease Therapeutics Market: Challenges

Figure 6: Global Crohn’s Disease Therapeutics Market: Trends

Figure 7: Global Crohn’s Disease Therapeutics Market: Opportunity

Figure 8: Global Crohn’s Disease Therapeutics Market: Restraint

Figure 9: Global Crohn’s Disease Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Figure 15: Global Crohn’s Disease Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Figure 23: Global Crohn’s Disease Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Table 10: Global Crohn’s Disease Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Crohn’s Disease Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Crohn’s Disease Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Crohn’s Disease Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson and Johnson Services Inc. Basic Information And Sales Area

Table 31: Johnson and Johnson Services Inc.. Products Portfolio

Table 32: Pfizer Inc. Basic Information And Sales Area

Table 33: Pfizer Inc.. Products Portfolio

Table 34: Allergan Basic Information And Sales Area

Table 35: Allergan. Products Portfolio

Table 36: AbbVie Inc. Basic Information And Sales Area

Table 37: AbbVie Inc.. Products Portfolio

Table 38: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 39: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 40: Celgene Corporation Basic Information And Sales Area

Table 41: Celgene Corporation. Products Portfolio

Table 42: Perrigo Company PLC Basic Information And Sales Area

Table 43: Perrigo Company PLC. Products Portfolio

Table 44: Ferring B.V. Basic Information And Sales Area

Table 45: Ferring B.V.. Products Portfolio

Table 46: Salix Pharmaceuticals Basic Information And Sales Area

Table 47: Salix Pharmaceuticals. Products Portfolio

Table 48: Gilead Sciences Inc. Basic Information And Sales Area

Table 49: Gilead Sciences Inc.. Products Portfolio

Table 50: Genentech Inc. Basic Information And Sales Area

Table 51: Genentech Inc.. Products Portfolio

Table 52: UCB India Private Limited Basic Information And Sales Area

Table 53: UCB India Private Limited. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Table 59: Global Crohn’s Disease Therapeutics Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Crohn’s Disease Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.70 million
Revenue forecast in 2033	24.98 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson and Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; UCB India Private Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing investments in research and development activities, focused on developing novel and more effective treatments, are also contributing to the growth of the market.

Restraints2 items

Stringent regulatory requirements and the need for lengthy clinical trials are also hindering the growth of the market, making it challenging for new treatments to enter the market.

Opportunities2 items

The increasing adoption of digital health technologies is also creating opportunities for the development of innovative treatment approaches, such as telemedicine and remote patient monitoring.

Challenges2 items

Managing the supply chain and ensuring the timely delivery of biologic therapies to patients is a significant challenge, due to the complex manufacturing and storage requirements of these products.

The Crohn’s Disease Therapeutics market is also facing challenges related to pricing and reimbursement, as the high costs of biologic therapies can limit patient access to these treatments.

Market Segmentation

Loading chart…

Crohn’s Disease Therapeutics Segmentation Breakdown6 items

Application

Hospitals

Ambulatory Surgical Centers

Types

Non-Surgical

Surgical

Regional Insights

Loading chart…

Competitive Landscape

Johnson and Johnson Services Inc. focuses on innovation pipeline

Pfizer Inc. prioritizes regional expansion

Allergan emphasizes premium pricing

AbbVie Inc. invests in vertical integration

Takeda Pharmaceutical Company Limited targets local manufacturing

Celgene Corporation explores OEM tie-ups

Key Crohn’s Disease Therapeutics Companies12 items

Johnson and Johnson Services Inc.

Pfizer Inc.

Allergan

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Celgene Corporation

Perrigo Company PLC

Ferring B.V.

Salix Pharmaceuticals

Gilead Sciences Inc.

Genentech Inc.

UCB India Private Limited

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce therapeutic products

Technology providers — develop innovative treatment technologies

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer patient support services

End users / buyers — receive therapeutic treatments

Regulators/standards bodies — establish treatment guidelines and approvals

Recent Industry Insights

Analyst Overview

Table of Contents